[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100596533":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":7,"centralContacts":13,"locations":19,"responsibleParty":37,"collaborators":7,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":57,"overallStatus":21,"whyStopped":7,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":68},{"fullName":5,"class":6},"The First Affiliated Hospital of Xiamen University","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","68Ga-MY6349","Each subject receives a single intravenous injection of 68Ga-MY6349 and undergoes PET\u002FCT imaging within the specified time.",[14],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Liang Zhao, MD, PhD","CONTACT","86 18818350620","wzhaoliang01@163.com",[20],{"facility":5,"status":21,"city":22,"state":23,"zip":24,"country":25,"countryCode":26,"cosmosGeoPoint":27,"geoPoint":32,"contacts":33},"RECRUITING","Xiamen","Fujian","361000","China","CN",{"type":28,"coordinates":29},"Point",[30,31],118.08187,24.47979,{"lat":31,"lon":30},[34],{"name":35,"role":16,"phone":36,"phoneExt":7,"email":18},"Liang Zhao","86 0592-213-7366",{"type":38,"investigatorFullName":7,"investigatorTitle":7,"investigatorAffiliation":7,"oldNameTitle":7,"oldOrganization":7},"SPONSOR","100596533","68ga-my6349-petct-in-solid-tumors-100596533",false,"NCT07046702","68Ga-MY6349 PET\u002FCT in Solid Tumors","68Ga-MY6349 PET\u002FCT in Solid Tumors and Compared With 18F-FDG PET\u002FCT","Inclusion Criteria:\n\n* adult patients (aged 18 years or older)\n* patients with suspected or newly diagnosed or previously treated malignant tumors (supporting evidence may include MRI, CT, tumor markers and pathology report)\n* patients who had scheduled both standard-of-care imaging and 68Ga-MY6349 PET\u002FCT scans\n* patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee\n\nExclusion Criteria:\n\n* patients with pregnancy\n* the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent","ALL","18 Years",{"count":49,"type":50},300,"ESTIMATED","OBSERVATIONAL","The objective of the study is to construct a noninvasive approach 68Ga-MY6349 PET\u002FCT to detect the Trop-2 expression of tumor lesions in patients with solid tumors and to identify patients benefiting from Trop-2 PET\u002FCT.",[54,55,56],"Solid Tumor","Trop2","PET\u002FCT",[58,55,56],"Solid tumor","2025-07-14",{"date":61,"type":62},"2025-07-15","ACTUAL",{"date":64,"type":62},"2024-12-10",{"date":66,"type":50},"2026-12-31",{"name":5,"class":6},1]